Replies to post #20246 on Biotech Values

[terry hallinan]

DewDiligence - PTIE CC,

I thought the only worthwhile comment from the CC was the observation that developing drugs for conditions such as IBS that lack a preclinical model is a bad business to be in.

I fear you are exactly right.

IBS is a bummer - whatever it is.

Best, Terry